Latest News

Merrimack's Phase I trial of MM-310 starts patient enrolment to treat solid tumours

US-based biopharmaceutical firm Merrimack Pharmaceuticals has started patient enrolment in a Phase I clinical trial of MM-310 for the treatment of solid...

Merrimack's Phase I trial of MM-310 starts patient enrolment to treat solid tumours

Akashi to initiate HALO-DMD-04 trial of HT-100 to treat DMD

Akashi to initiate HALO-DMD-04 trial of HT-100 to treat DMD

Intec Pharma begins Phase I trial of AP-CBD / THC to treat low back pain and fibromyalgia

Intec Pharma begins Phase I trial of AP-CBD / THC to treat low back pain and fibromyalgia

EnGeneIC begins dosing in Phase I trial of EDV nanocells to treat GBM in US

Australian-based biopharmaceutical firm EnGeneIC has begun dosing patients in a Phase I clinical trial of its EDV nanocells for the treatment of recurrent glioblastoma multiforme (GBM)...

EnGeneIC begins dosing in Phase I trial of EDV nanocells to treat GBM in US

Galapagos begins Phase I trial of GLPG0367 to treat cystic fibrosis

Belgium-based biopharmaceutical firm Galapagos has begun the Phase I clinical trial of GLPG3067 for the treatment of patients with cystic fibrosis...

Galapagos begins Phase I trial of GLPG0367 to treat cystic fibrosis

Blueprint begins Phase I trial of BLU-667 to treat solid tumours with RET alteration

Blueprint begins Phase I trial of BLU-667 to treat solid tumours with RET alteration

Apexigen begins enrolment in APX005M combination therapy Phase I/II trial for melanoma

Biopharmaceutical firm Apexigen has begun enrolling patients in a Phase I/II clinical trial of APX005M in combination with pembrolizumab (Keytruda) to treat metastatic melanoma....

Apexigen begins enrolment in APX005M combination therapy Phase I/II trial for melanoma

Novartis' new trial results demonstrate Cosentyx's ability to modify course of psoriasis

Swiss-based healthcare company Novartis has reported positive results from the extension A2302E1 trial of Cosentyx (secukinumab), indicating the product's ability to modify the course...

Novartis' new trial results demonstrate Cosentyx's ability to modify course of psoriasis

Ergomed begins Phase II trial of peprostat to control intraoperative surgical bleeding

UK-based pharmaceutical company Ergomed has begun patient enrolment in a proof-of-concept Phase IIb clinical trial of peprostat to control intraoperative surgical...

Ergomed begins Phase II trial of peprostat to control intraoperative surgical bleeding

Galena reports positive results from Phase I/IIa cancer trial of GALE-301

Galena reports positive results from Phase I/IIa cancer trial of GALE-301

Boehringer Ingelheim begins enrolment in Phase III trial of nintedanib to treat PF-ILD

German pharmaceutical firm Boehringer Ingelheim has begun patient enrolment in the Phase III clinical trial of nintedanib (OFEV) to treat progressive fibrosing interstital lung disease...

Boehringer Ingelheim begins enrolment in Phase III trial of nintedanib to treat PF-ILD

Nordic Nanovector begins dosing in Phase I trial of Betalutin for DLBCL

Nordic Nanovector begins dosing in Phase I trial of Betalutin for DLBCL

NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP

UK-based biopharmaceutical company NightstaRx (Nightstar) has initiated enrolment and dosing in a Phase I/II clinical trial of its gene therapy 'AAV- XLRPGR' for the treatment of patients...

NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP

Pharnext begins Phase III extension trial of PXT3003 to treat type 1A CMT

French biopharmaceutical company Pharnext has begun the Phase III extension trial (PLEO-CMT-FU) of PXT3003 for the treatment of patients with mild-to-moderate charcot-marie-tooth disease type...

Pharnext begins Phase III extension trial of PXT3003 to treat type 1A CMT

Alkermes starts Phase III trial of ALKS 8700 to treat multiple sclerosis

Ireland-based biopharmaceutical firm Alkermes has started a Phase III clinical trial of ALKS 8700 for the treatment of relapsing forms of multiple sclerosis...

Alkermes starts Phase III trial of ALKS 8700 to treat multiple sclerosis

BriaCell to begin Phase I/IIa clinical trial of BriaVax to treat breast cancer

BriaCell to begin Phase I/IIa clinical trial of BriaVax to treat breast cancer

MUK Phase Ib trial to assess Reolysin + Imnovid / Revlimid combination to treat myeloma

Cancer charity Myeloma UK and biotechnolgy firm Oncolytics Biotech have commenced a Phase Ib MUK eleven trial of Reolysin (pelareorep) in combination with Imnovid (pomalidomide) or...

MUK Phase Ib trial to assess Reolysin + Imnovid / Revlimid combination to treat myeloma

Trial finds antibody-drug conjugate IMMU-132 shrinks triple negative breast tumours

Trial finds antibody-drug conjugate IMMU-132 shrinks triple negative breast tumours

Catalyst Pharmaceuticals reports positive results from MuSK-MG trial of Firdapse to treat MG

Catalyst Pharmaceuticals has reported positive top-line results from the MuSK-MG clinical trial of Firdapse to treat patients with myasthenia gravis...

Catalyst Pharmaceuticals reports positive results from MuSK-MG trial of Firdapse to treat MG

Celerion deploys VCT fingerprint technology at clinical trial facilities

Clinical research solutions provider Celerion has deployed the Verified Clinical Trials (VCT) biometric fingerprint technology to prevent dual enrolment in clinical...

Celerion deploys VCT fingerprint technology at clinical trial facilities

Lung Therapeutics begins Phase Ia/b trial of LTI-01 for pleural effusions in Australia and New Zealand

Lung Therapeutics begins Phase Ia/b trial of LTI-01 for pleural effusions in Australia and New Zealand
cachename:Newscachekey:rd-137342983_1031809799_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_80855758